Mazama Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mazama Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-48,097	Closed	-$6.05M	–	171
2015 Q4	$6.05M	Buy	+48,097	New	+$5.81M	1.11%	27
2015 Q3	–	Sell	-20,634	Closed	-$2.55M	–	308
2015 Q2	$2.55M	Sell	20,634 -36,010	-64%	-$4.54M	0.51%	66
2015 Q1	$6.68M	Buy	56,644 +16,039	+40%	+$1.92M	1.37%	10
2014 Q4	$4.82M	Sell	40,605 -7,106	-15%	-$800K	1.11%	20
2014 Q3	$5.36M	Buy	+47,711	New	+$4.54M	1.36%	12
2014 Q1	–	Sell	-220	Closed	-$16K	–	286
2013 Q4	$16K	Buy	+220	New	+$15.3K	0.01%	232

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Mazama Capital Management's VRTX Position: Q1 2016 in Review

Mazama Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2016, closing a stake of 48,097 shares — an estimated $6.05M sold.

Mazama Capital Management first reported a position in VRTX in Q4 2013 and held it in 6 quarters. The position peaked at $6.68M in Q1 2015. 503 funds tracked by Wall St. Rank hold VRTX as of Q1 2016.

Mazama Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Mazama Capital Management sold 48,097 Vertex Pharmaceuticals shares in Q1 2016, an estimated $6.05M.
Mazama Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2013 and held it in 6 quarters.
Mazama Capital Management's Vertex Pharmaceuticals position peaked at $6.68M in Q1 2015.
503 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2016.

Based on Mazama Capital Management's 13F filing for Q1 2016.